Evidence map›Paper›PMID 36751700›Full record

ArticleJournal of Zhejiang University. Science. B2023

Dexin Yang, Yuqin Feng, Haohua Lu, Kelie Chen, Jinming Xu, Peiwei Li, Tianru Wang, Dajing Xia, Yihua Wu

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Zhejiang University. Science. B, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 3 countries.

Dexin YangDepartment of Toxicology of School of Public Health, and Department of Gynecologic Oncology of Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China.
Yuqin FengDepartment of Toxicology of School of Public Health, and Department of Gynecologic Oncology of Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China.
Haohua LuDepartment of Toxicology of School of Public Health, and Department of Gynecologic Oncology of Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China.
Kelie ChenDepartment of Toxicology of School of Public Health, and Department of Gynecologic Oncology of Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China.
Jinming XuDepartment of Thoracic Surgery, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
Peiwei LiDepartment of Gastroenterology, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China.
Tianru WangEpidemiology Stream, Dalla Lana School of Public Health, University of Toronto, Toronto, M5S 2E8, Canada.
Dajing XiaDepartment of Toxicology of School of Public Health, and Department of Gynecologic Oncology of Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China. dxia@zju.edu.cn.
Yihua WuDepartment of Toxicology of School of Public Health, and Department of Gynecologic Oncology of Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China. georgewu@zju.edu.cn.
Women's Hospital, School of Medicine, Zhejiang University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNSecond Affiliated Hospital of Zhejiang University · CNThe University of Texas MD Anderson Cancer Center · USUniversity of Toronto · CAZhejiang University · CN

Funding

the Fundamental Research Funds for the Central Universities, and the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (CIFMS) 2019-I2M-5-044the National Natural Science Foundation of China 21976155, 81802881 and 81773016the Zhejiang Provincial Natural Science Foundation of China LY18C060001
6 · The paper itself

Abstract

This study aimed to identify subtypes of genomic variants associated with the efficacy of immune checkpoint inhibitors (ICIs) by conducting systematic literature search in electronic databases up to May 31, 2021. The main outcomes including overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and durable clinical benefit (DCB) were correlated with tumor genomic features. A total of 1546 lung cancer patients with available genomic variation data were included from 14 studies. The Kirsten rat sarcoma viral oncogene homolog

Indexed as

Carcinoma, Non-Small-Cell LungExtracellular Matrix ProteinsImmune Checkpoint InhibitorsLung NeoplasmsErbB ReceptorsHumansMutationProtein Kinase InhibitorsProto-Oncogene Proteins p21(ras)Treatment OutcomeErbB ReceptorsExtracellular Matrix ProteinsImmune Checkpoint InhibitorsProtein Kinase InhibitorsProto-Oncogene Proteins p21(ras)USH2A protein, humanEpidermal growth factor receptor (EGFR) mutationImmune checkpoint inhibitor (ICI)Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation combined with tumor protein P53 (TP53) mutationLung cancerUsher syndrome type-2A (USH2A) missense mutation

Identifiers

PMID36751700
PMCPMC10260284
OpenAlexW4319460787

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.